The frequency with which MYC and HSF1 are co-amplified further indicates that co-amplification provides a growth or survival advantage for tumor cells, particularly for HGSOC compared with other tumor types, based on the high amplification frequency for HSF1 and MYC in 34% (199/579) and 42% (243/579) of patients, respectively (Fig. 1F–H). Here, HSF1 is linked to neoplasm.